TLM-007

**TLM-007** is an investigational Therillume pipeline asset being developed by **TLM** for **glioblastoma multiforme**. Publicly available pipeline material identifies it only by the internal code **TLM-007** and places it in **Phase 1** development for GBM, but does not disclose a molecular target, active ingredient, modality, formulation details, route of administration, or mechanism of action. Based on the available source material, it should therefore be treated as an **early-stage, undisclosed oncology drug candidate** rather than a fully characterized named therapeutic.

Other names

TLM-007-TLM-Glioblastoma Multiforme (GBM)